Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Crit Care
2023 Nov 09;271:435. doi: 10.1186/s13054-023-04720-2.
Show Gene links
Show Anatomy links
Moving toward a contemporary classification of drug-induced kidney disease.
Karimzadeh I
,
Barreto EF
,
Kellum JA
,
Awdishu L
,
Murray PT
,
Ostermann M
,
Bihorac A
,
Mehta RL
,
Goldstein SL
,
Kashani KB
,
Kane-Gill SL
.
???displayArticle.abstract???
Drug-induced kidney disease (DIKD) accounts for about one-fourth of all cases of acute kidney injury (AKI) in hospitalized patients, especially in critically ill setting. There is no standard definition or classification system of DIKD. To address this, a phenotype definition of DIKD using expert consensus was introduced in 2015. Recently, a novel framework for DIKD classification was proposed that incorporated functional change and tissue damage biomarkers. Medications were stratified into four categories, including "dysfunction without damage," "damage without dysfunction," "both dysfunction and damage," and "neither dysfunction nor damage" using this novel framework along with predominant mechanism(s) of nephrotoxicity for drugs and drug classes. Here, we briefly describe mechanisms and provide examples of drugs/drug classes related to the categories in the proposed framework. In addition, the possible movement of a patient's kidney disease between certain categories in specific conditions is considered. Finally, opportunities and barriers to adoption of this framework for DIKD classification in real clinical practice are discussed. This new classification system allows congruencies for DIKD with the proposed categorization of AKI, offering clarity as well as consistency for clinicians and researchers.
Awdishu,
The 6R's of drug induced nephrotoxicity.
2017, Pubmed
Awdishu,
The 6R's of drug induced nephrotoxicity.
2017,
Pubmed
Barnett,
Nephrotoxicity and Renal Pathophysiology: A Contemporary Perspective.
2018,
Pubmed
Barreto,
Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review.
2019,
Pubmed
Blair,
Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review.
2021,
Pubmed
Chen,
Management of Presumed Acute Kidney Injury during Hypertensive Therapy: Stay Calm and Carry on?
2020,
Pubmed
Chávez-Iñiguez,
Acute Kidney Injury Caused by Obstructive Nephropathy.
2020,
Pubmed
Côté,
A ray of hope in the discord: is adding piperacillin-tazobactam to vancomycin truly more nephrotoxic?
2022,
Pubmed
Davani-Davari,
Potential Adverse Effects of Creatine Supplement on the Kidney in Athletes and Bodybuilders.
2018,
Pubmed
Dennen,
Acute kidney injury in the intensive care unit: an update and primer for the intensivist.
2010,
Pubmed
Desai,
Kidney Damage and Stress Biomarkers for Early Identification of Drug-Induced Kidney Injury: A Systematic Review.
2022,
Pubmed
Endre,
Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.
2013,
Pubmed
Eron,
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
2013,
Pubmed
Erstad,
Usefulness of the Biomarker TIMP-2•IGFBP7 for Acute Kidney Injury Assessment in Critically Ill Patients: A Narrative Review.
2022,
Pubmed
Farouk,
The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?
2020,
Pubmed
Frazee,
Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project.
2017,
Pubmed
Gray,
Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method.
2022,
Pubmed
Gupta,
Acute Kidney Injury in Critically Ill Patients with Cancer.
2022,
Pubmed
Hall,
Drug-induced renal Fanconi syndrome.
2014,
Pubmed
Inker,
Estimating glomerular filtration rate from serum creatinine and cystatin C.
2012,
Pubmed
Juncos,
Pathophysiology of Acute Kidney Injury in Critical Illness: A Narrative Review.
2022,
Pubmed
Kan,
Vancomycin-Associated Acute Kidney Injury: A Narrative Review from Pathophysiology to Clinical Application.
2022,
Pubmed
Kane-Gill,
Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury.
2017,
Pubmed
Karimzadeh,
Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.
2013,
Pubmed
Karimzadeh,
Moving toward a contemporary classification of drug-induced kidney disease.
2023,
Pubmed
Karimzadeh,
A double-blinded, placebo-controlled, multicenter clinical trial of N-acetylcysteine for preventing amphotericin B-induced nephrotoxicity.
2015,
Pubmed
Kellum,
Acute kidney injury.
2021,
Pubmed
Khorashadi,
Proenkephalin: A New Biomarker for Glomerular Filtration Rate and Acute Kidney Injury.
2020,
Pubmed
Kim,
Pathophysiology of Drug-Induced Hyponatremia.
2022,
Pubmed
Koteff,
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
2013,
Pubmed
Kwiatkowska,
The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage.
2021,
Pubmed
Lepist,
Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat.
2014,
Pubmed
Liu,
Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis.
2012,
Pubmed
Lopez-Novoa,
New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view.
2011,
Pubmed
Makris,
Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes.
2016,
Pubmed
Mehta,
Phenotype standardization for drug-induced kidney disease.
2015,
Pubmed
Meraz-Muñoz,
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.
2021,
Pubmed
Miano,
Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
2022,
Pubmed
Moore,
Management of Acute Kidney Injury: Core Curriculum 2018.
2018,
Pubmed
Moroni,
Secondary Membranous Nephropathy. A Narrative Review.
2020,
Pubmed
Murphy,
Drug-related causes attributed to acute kidney injury and their documentation in intensive care patients.
2023,
Pubmed
Ostermann,
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.
2020,
Pubmed
Ostermann,
Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.
2020,
Pubmed
Ostermann,
Acute kidney injury 2016: diagnosis and diagnostic workup.
2016,
Pubmed
Ostermann,
Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults.
2018,
Pubmed
Parikh,
"Permissive AKI" with treatment of heart failure.
2019,
Pubmed
Parsels,
Recurrent Renal Dysfunction Secondary to Probable Piperacillin-Tazobactam-Induced Acute Interstitial Nephritis.
2021,
Pubmed
Perazella,
Drug-Induced Acute Kidney Injury.
2022,
Pubmed
Perazella,
Renal vulnerability to drug toxicity.
2009,
Pubmed
Perazella,
The Crystalline Nephropathies.
2021,
Pubmed
Raghavan,
Acute interstitial nephritis - a reappraisal and update.
2014,
Pubmed
Ronco,
Acute kidney injury.
2019,
Pubmed
Sampaio de Souza Garms,
The Role of Urinary Biomarkers as Diagnostic and Prognostic Predictors of Acute Kidney Injury Associated With Vancomycin.
2021,
Pubmed
Szalat,
Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia.
2018,
Pubmed
Vijayan,
Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment.
2016,
Pubmed
Yong,
Predictive value of serum cystatin C for acute kidney injury in adults: a meta-analysis of prospective cohort trials.
2017,
Pubmed
Zarbock,
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.
2023,
Pubmed
